Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chong Chyn ChuaAndrew W RobertsJohn ReynoldsChun Yew FongStephen B TingJessica M SalmonSarah MacRaildAdam IveyIng Soo TiongShaun FlemingFiona C BrownSun LooIan J MajewskiStefan K BohlanderAndrew H WeiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Venetoclax combined with 5 + 2 induction chemotherapy was safe and tolerable in fit older patients with AML. Although the optimal postremission therapy remains to be determined, the high remission rate in de novo AML warrants additional investigation (ANZ Clinical Trial Registry No. ACTRN12616000445471).
Keyphrases
- acute myeloid leukemia
- clinical trial
- locally advanced
- chronic lymphocytic leukemia
- allogeneic hematopoietic stem cell transplantation
- study protocol
- middle aged
- open label
- community dwelling
- phase iii
- randomized controlled trial
- squamous cell carcinoma
- physical activity
- rectal cancer
- radiation therapy
- chemotherapy induced
- replacement therapy